Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the ...
Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado.
Biohaven jumps after FDA accepts Vyglyxia's NDA resubmission, but pipeline focus and approval risks cloud the outlook. Read ...
It was a year 5 market day at Newport Lakes Primary School that sparked young Brandon Winkworth’s determination to raise ...
You wake up one morning, open your stock chart, and find that a stock you hold has jumped by 50%. Or, without any warning, it ...
Biohaven secured FDA acceptance of its resubmitted new drug application for Vyglxia, or troriluzole, in spinocerebellar ...
GlobalData on MSN
Biohaven partners with Ono in $100m IgG degrader deal
The transaction grants Ono exclusive rights for candidates BHV-1300, BHV-1310, and BHV-1320 across Taiwan, South Korea, and Japan.
The FDA issued a Complete Response Letter last November, declining to approve the drug. ・The FDA set a target deadline for the first quarter of 2027. ・Biohaven held about $270.5 million in cash, ...
Biohaven Ltd. BHVN stock is surging on Thursday with a session volume of 10.293 million versus an average volume of 2.585 ...
NEW HAVEN, Conn., Sept. 28, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results